ENLV
Enlivex
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Enlivex announces a cost-reduction plan to prioritize its Phase 2b Allocetra trial in age-related primary moderate-to-severe knee osteoarthritisOct 19, 2026
- Enlivex received FDA RMAT designation for Allocetra in age-related knee osteoarthritisJul 13, 2026
- Enlivex received an Australian patent covering the use of Allocetra in osteoarthritis patientsJun 15, 2026
- Enlivex dosed the first U.S. patient in its Phase 2b Allocetra knee osteoarthritis trialMay 18, 2026
- Enlivex received a second regulatory approval for its Phase 2b Allocetra trial in knee osteoarthritisApr 21, 2026